Compare ARK Genomic Revolution ETF (ARKG) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Bank of Nova Scotia — how do they compare? ARK Genomic Revolution ETF trades at $40.68, while Bank of Nova Scotia trades at $87.84 (market cap $107.21B). The key difference: Bank of Nova Scotia pays a 3.67% dividend while ARK Genomic Revolution ETF pays none, and Bank of Nova Scotia is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | BNS | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $87.59 |
52-Week Low | $23.09 | $54.50 |
Market Cap | — | $107.21B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BNS trades at $87.59, up 1.78% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.47, exceeding expectations, and maintains a net income margin of 24.86%. Recent news highlights dividend strength and the acquisition of MapleMark Bank to bolster growth. Analyst consensus is 53% buy, with a P/E of 17.15 indicating reasonable valuation.
Outlook is positive due to consistent earnings performance and strategic acquisitions, but risks include high debt levels and economic sensitivity. The stock offers income appeal with a $1.14 dividend, yet investors should monitor credit provisions amid soft economic conditions noted in Q2 2026 reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
